Attached files
file | filename |
---|---|
EX-31.1 - EX-31.1 - Histogen Inc. | cnat-ex311_6.htm |
EX-32.2 - EX-32.2 - Histogen Inc. | cnat-ex322_7.htm |
EX-32.1 - EX-32.1 - Histogen Inc. | cnat-ex321_10.htm |
EX-31.2 - EX-31.2 - Histogen Inc. | cnat-ex312_9.htm |
EX-10.39 - EX-10.39 - Histogen Inc. | cnat-ex1039_306.htm |
EX-4.5 - EX-4.5 - Histogen Inc. | cnat-ex45_307.htm |
10-K - 10-K - Histogen Inc. | cnat-10k_20191231.htm |
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) |
Registration Statement (Form S-8 No. 333-211162) pertaining to the Conatus Pharmaceuticals Inc. 2013 Incentive Award Plan, |
(2) |
Registration Statement (Form S-8 No. 333-190134) pertaining to the Conatus Pharmaceuticals Inc. 2013 Incentive Award Plan, the Conatus Pharmaceuticals Inc. 2006 Equity Incentive Award Plan and the Conatus Pharmaceuticals Inc. 2013 Employee Stock Purchase Plan, |
(3) Registration Statement (Form S-3 No. 333-220014) of Conatus Pharmaceuticals Inc.,
(4) Registration Statement (Form S-8 No. 333-223552) pertaining to the Conatus Pharmaceuticals Inc. 2013 Incentive Award Plan and a Non-Qualified Inducement Stock Option Grant Notice and Stock Option Agreement, and
(5) Registration Statement (Form S-4 No. 333-236332) of Conatus Pharmaceuticals Inc.;
of our report dated March 11, 2020, with respect to the financial statements of Conatus Pharmaceuticals Inc. included in this Annual Report (Form 10-K) of Conatus Pharmaceuticals Inc. for the year ended December 31, 2019.
/s/ Ernst & Young LLP
San Diego, California
March 11, 2020